GNA12

Across TCGA pan-cancer cohorts, GNA12 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GNA12 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GNA12 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GNA12 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where GNA12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.245	0.875	.008	19	view →
PDAC	OS	Quartile	III,IV	0.146	0.850	.010	12	view →
LSCC	OS	Quartile	II,III,IV	0.642	0.941	.021	7	view →
HNSC	DFS	Tertile	All	1.000	0.922	.008	7	view →
CCRCC	OS	Median	II,III,IV	0.554	1.000	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GNA12–LUAD (DFS)

Open the LUAD breakdown →